nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—Hoarseness—Varenicline—nicotine dependence	0.0609	0.0835	CcSEcCtD
Danazol—Thrombosis—Varenicline—nicotine dependence	0.0378	0.0519	CcSEcCtD
Danazol—CCL2—cardiovascular system—nicotine dependence	0.0338	0.166	CbGeAlD
Danazol—Dysphonia—Varenicline—nicotine dependence	0.0325	0.0446	CcSEcCtD
Danazol—Acne—Varenicline—nicotine dependence	0.0318	0.0436	CcSEcCtD
Danazol—Leukocytosis—Varenicline—nicotine dependence	0.0285	0.0391	CcSEcCtD
Danazol—CCL2—midbrain—nicotine dependence	0.0264	0.13	CbGeAlD
Danazol—Sleep disorder—Varenicline—nicotine dependence	0.0225	0.0308	CcSEcCtD
Danazol—GNRHR—brain—nicotine dependence	0.0212	0.104	CbGeAlD
Danazol—Visual disturbance—Varenicline—nicotine dependence	0.0205	0.0281	CcSEcCtD
Danazol—SHBG—cardiovascular system—nicotine dependence	0.0197	0.0969	CbGeAlD
Danazol—Migraine—Varenicline—nicotine dependence	0.0191	0.0262	CcSEcCtD
Danazol—Affect lability—Varenicline—nicotine dependence	0.0191	0.0262	CcSEcCtD
Danazol—Irritability—Varenicline—nicotine dependence	0.0186	0.0254	CcSEcCtD
Danazol—Mood swings—Varenicline—nicotine dependence	0.0184	0.0252	CcSEcCtD
Danazol—Abdominal pain upper—Varenicline—nicotine dependence	0.0178	0.0243	CcSEcCtD
Danazol—PGR—cardiovascular system—nicotine dependence	0.0177	0.0873	CbGeAlD
Danazol—Cramp muscle—Varenicline—nicotine dependence	0.0175	0.024	CcSEcCtD
Danazol—CCL2—brain—nicotine dependence	0.0166	0.0815	CbGeAlD
Danazol—Photosensitivity reaction—Varenicline—nicotine dependence	0.0153	0.021	CcSEcCtD
Danazol—Weight increased—Varenicline—nicotine dependence	0.0153	0.021	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.0148	0.0204	CcSEcCtD
Danazol—Acute coronary syndrome—Varenicline—nicotine dependence	0.0148	0.0202	CcSEcCtD
Danazol—Myocardial infarction—Varenicline—nicotine dependence	0.0147	0.0201	CcSEcCtD
Danazol—AR—cardiovascular system—nicotine dependence	0.0141	0.0695	CbGeAlD
Danazol—ESR1—cardiovascular system—nicotine dependence	0.0139	0.0683	CbGeAlD
Danazol—Visual impairment—Varenicline—nicotine dependence	0.013	0.0178	CcSEcCtD
Danazol—Erythema multiforme—Varenicline—nicotine dependence	0.0127	0.0174	CcSEcCtD
Danazol—Chills—Varenicline—nicotine dependence	0.0121	0.0165	CcSEcCtD
Danazol—Back pain—Varenicline—nicotine dependence	0.0113	0.0155	CcSEcCtD
Danazol—Muscle spasms—Varenicline—nicotine dependence	0.0113	0.0154	CcSEcCtD
Danazol—Vision blurred—Varenicline—nicotine dependence	0.011	0.0151	CcSEcCtD
Danazol—Tremor—Varenicline—nicotine dependence	0.011	0.015	CcSEcCtD
Danazol—Vertigo—Varenicline—nicotine dependence	0.0105	0.0144	CcSEcCtD
Danazol—Syncope—Varenicline—nicotine dependence	0.0105	0.0144	CcSEcCtD
Danazol—Palpitations—Varenicline—nicotine dependence	0.0103	0.0142	CcSEcCtD
Danazol—Loss of consciousness—Varenicline—nicotine dependence	0.0103	0.0141	CcSEcCtD
Danazol—Convulsion—Varenicline—nicotine dependence	0.0101	0.0139	CcSEcCtD
Danazol—Hypertension—Varenicline—nicotine dependence	0.0101	0.0139	CcSEcCtD
Danazol—Arthralgia—Varenicline—nicotine dependence	0.00996	0.0137	CcSEcCtD
Danazol—Anxiety—Varenicline—nicotine dependence	0.00993	0.0136	CcSEcCtD
Danazol—SHBG—brain—nicotine dependence	0.00966	0.0475	CbGeAlD
Danazol—Oedema—Varenicline—nicotine dependence	0.00955	0.0131	CcSEcCtD
Danazol—Shock—Varenicline—nicotine dependence	0.0094	0.0129	CcSEcCtD
Danazol—Thrombocytopenia—Varenicline—nicotine dependence	0.00935	0.0128	CcSEcCtD
Danazol—Tachycardia—Varenicline—nicotine dependence	0.00932	0.0128	CcSEcCtD
Danazol—Hyperhidrosis—Varenicline—nicotine dependence	0.00923	0.0127	CcSEcCtD
Danazol—PGR—brain—nicotine dependence	0.0087	0.0428	CbGeAlD
Danazol—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.0087	0.0119	CcSEcCtD
Danazol—Dyspepsia—Varenicline—nicotine dependence	0.00841	0.0115	CcSEcCtD
Danazol—Fatigue—Varenicline—nicotine dependence	0.00824	0.0113	CcSEcCtD
Danazol—Constipation—Varenicline—nicotine dependence	0.00817	0.0112	CcSEcCtD
Danazol—CYP19A1—brain—nicotine dependence	0.00783	0.0385	CbGeAlD
Danazol—Urticaria—Varenicline—nicotine dependence	0.00759	0.0104	CcSEcCtD
Danazol—Body temperature increased—Varenicline—nicotine dependence	0.00755	0.0104	CcSEcCtD
Danazol—AR—brain—nicotine dependence	0.00693	0.0341	CbGeAlD
Danazol—Asthenia—Varenicline—nicotine dependence	0.00685	0.0094	CcSEcCtD
Danazol—ESR1—brain—nicotine dependence	0.00681	0.0335	CbGeAlD
Danazol—Pruritus—Varenicline—nicotine dependence	0.00676	0.00927	CcSEcCtD
Danazol—Dizziness—Varenicline—nicotine dependence	0.00632	0.00866	CcSEcCtD
Danazol—Vomiting—Varenicline—nicotine dependence	0.00607	0.00833	CcSEcCtD
Danazol—Rash—Varenicline—nicotine dependence	0.00602	0.00826	CcSEcCtD
Danazol—Dermatitis—Varenicline—nicotine dependence	0.00602	0.00825	CcSEcCtD
Danazol—Headache—Varenicline—nicotine dependence	0.00598	0.00821	CcSEcCtD
Danazol—Nausea—Varenicline—nicotine dependence	0.00567	0.00778	CcSEcCtD
Danazol—GNRHR—Peptide GPCRs—OPRM1—nicotine dependence	0.00447	0.0661	CbGpPWpGaD
Danazol—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00334	0.0494	CbGpPWpGaD
Danazol—CYP19A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0033	0.0488	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00278	0.0412	CbGpPWpGaD
Danazol—CYP19A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00271	0.0401	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—TAS2R16—nicotine dependence	0.00255	0.0377	CbGpPWpGaD
Danazol—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00235	0.0347	CbGpPWpGaD
Danazol—CCL2—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.0023	0.034	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00173	0.0256	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00154	0.0228	CbGpPWpGaD
Danazol—CYP19A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00153	0.0226	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00144	0.0213	CbGpPWpGaD
Danazol—CYP19A1—Biological oxidations—CYP2A7—nicotine dependence	0.00144	0.0213	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—TAS2R16—nicotine dependence	0.00143	0.0211	CbGpPWpGaD
Danazol—CYP19A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00142	0.021	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00141	0.0209	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—TAS2R16—nicotine dependence	0.00131	0.0193	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—OPRM1—nicotine dependence	0.00117	0.0174	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00116	0.0171	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—FGD1—nicotine dependence	0.00113	0.0167	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—FGD1—nicotine dependence	0.00112	0.0166	CbGpPWpGaD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00111	0.0165	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—OPRM1—nicotine dependence	0.00107	0.0159	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00105	0.0155	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—FGD1—nicotine dependence	0.00103	0.0152	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00102	0.0151	CbGpPWpGaD
Danazol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000975	0.0144	CbGpPWpGaD
Danazol—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000962	0.0142	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—DRD2—nicotine dependence	0.000848	0.0126	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TAS2R16—nicotine dependence	0.000844	0.0125	CbGpPWpGaD
Danazol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00079	0.0117	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—DRD2—nicotine dependence	0.000776	0.0115	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TAS2R16—nicotine dependence	0.000772	0.0114	CbGpPWpGaD
Danazol—PGR—Gene Expression—CCAR1—nicotine dependence	0.000749	0.0111	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FGD1—nicotine dependence	0.000662	0.0098	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—OPRM1—nicotine dependence	0.000607	0.00898	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FGD1—nicotine dependence	0.000606	0.00896	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—OPRM1—nicotine dependence	0.000602	0.00891	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—AKR1B10—nicotine dependence	0.000585	0.00866	CbGpPWpGaD
Danazol—AR—Gene Expression—CCAR1—nicotine dependence	0.00057	0.00844	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—OPRM1—nicotine dependence	0.000551	0.00815	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—AKR1B10—nicotine dependence	0.000535	0.00792	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TAS2R16—nicotine dependence	0.000487	0.0072	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000445	0.00659	CbGpPWpGaD
Danazol—ESR1—Gene Expression—CCAR1—nicotine dependence	0.000439	0.0065	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—DRD2—nicotine dependence	0.000439	0.00649	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—DRD2—nicotine dependence	0.000435	0.00644	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.00042	0.00621	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000414	0.00613	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—WASF2—nicotine dependence	0.000412	0.0061	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—DRD2—nicotine dependence	0.000398	0.00589	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—WASF1—nicotine dependence	0.000395	0.00585	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FGD1—nicotine dependence	0.000382	0.00565	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—WASF2—nicotine dependence	0.000377	0.00558	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—WASF1—nicotine dependence	0.000361	0.00535	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—OPRM1—nicotine dependence	0.000356	0.00527	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—AKR1B10—nicotine dependence	0.000337	0.00499	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—OPRM1—nicotine dependence	0.000325	0.00482	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000286	0.00423	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—DRD2—nicotine dependence	0.000257	0.00381	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CYP2A7—nicotine dependence	0.000246	0.00364	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—WASF2—nicotine dependence	0.000238	0.00352	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—DRD2—nicotine dependence	0.000235	0.00348	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—WASF1—nicotine dependence	0.000228	0.00337	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FGD1—nicotine dependence	0.000224	0.00332	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—OPRM1—nicotine dependence	0.000205	0.00304	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000198	0.00293	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—DRD2—nicotine dependence	0.000148	0.0022	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—WASF2—nicotine dependence	0.00014	0.00206	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—WASF1—nicotine dependence	0.000134	0.00198	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—OPRM1—nicotine dependence	0.00012	0.00178	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—DRD2—nicotine dependence	8.71e-05	0.00129	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYP2A7—nicotine dependence	7.18e-05	0.00106	CbGpPWpGaD
